Dr. Somaiah on Next Steps for CMB305 in Soft Tissue Sarcoma

Neeta Somaiah, MD
Published: Wednesday, Aug 02, 2017



Neeta Somaiah, MD, assistant professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the next steps following the phase I findings of the CMB305 trial in patients with NY-ESO-1–positive recurrent soft tissue sarcoma.

The initial next step is to determine the patient population who will benefit the most from this regimen, explains Somaiah.

This drug can be compared against other regimens in the maintenance or third-line setting in order to determine if CMB305 will help a patient delay progression, states Somaiah.



Neeta Somaiah, MD, assistant professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the next steps following the phase I findings of the CMB305 trial in patients with NY-ESO-1–positive recurrent soft tissue sarcoma.

The initial next step is to determine the patient population who will benefit the most from this regimen, explains Somaiah.

This drug can be compared against other regimens in the maintenance or third-line setting in order to determine if CMB305 will help a patient delay progression, states Somaiah.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Publication Bottom Border
Border Publication
x